Kyntra Reports Phase 3 MATTERHORN Data For Roxadustat In LR-MDS; U.S. Phase 3 Planned In H2 2026

Kyntra Bio released new Phase 3 MATTERHORN trial data for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome. The update is clinically relevant for the company’s pipeline, but the article provides no trial outcome details, statistical results, or regulatory decision, limiting immediate market impact.

Analysis

Kyntra Bio released new Phase 3 MATTERHORN trial data for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome. The update is clinically relevant for the company’s pipeline, but the article provides no trial outcome details, statistical results, or regulatory decision, limiting immediate market impact.